- Популярные видео
- Авто
- Видео-блоги
- ДТП, аварии
- Для маленьких
- Еда, напитки
- Животные
- Закон и право
- Знаменитости
- Игры
- Искусство
- Комедии
- Красота, мода
- Кулинария, рецепты
- Люди
- Мото
- Музыка
- Мультфильмы
- Наука, технологии
- Новости
- Образование
- Политика
- Праздники
- Приколы
- Природа
- Происшествия
- Путешествия
- Развлечения
- Ржач
- Семья
- Сериалы
- Спорт
- Стиль жизни
- ТВ передачи
- Танцы
- Технологии
- Товары
- Ужасы
- Фильмы
- Шоу-бизнес
- Юмор
REALiTEC cohort 2: teclistamab shows favorable real-world outcomes in R/R myeloma
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, presents data from cohort 2 of the REALiTEC study (NCT06285318) evaluating the real-world use of teclistamab in patients with relapsed/refractory (R/R) multiple myeloma (MM). He reports favorable progression-free survival (PFS) and safety outcomes compared with the REALiTEC cohort 1, attributable to increased use of immunoglobulin replacement therapy, and concludes that the data support the use of teclistamab in routine clinical practice. This interview took place at the 12th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Видео REALiTEC cohort 2: teclistamab shows favorable real-world outcomes in R/R myeloma канала VJHemOnc – Video Journal of Hematology & HemOnc
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Видео REALiTEC cohort 2: teclistamab shows favorable real-world outcomes in R/R myeloma канала VJHemOnc – Video Journal of Hematology & HemOnc
Speaker: Rakesh Popat Institution: University College London Hospitals Event: COMy 2026 Format: Interview Subject: Multiple Myeloma Field: Trial Updates Field: Clinical Practice Field: Treatment Field: Real-World Data Field: Immuno-Oncology Medicines: Antibodies Medicines: Teclistamab Trial: REALiTEC bispecifics MM NCT06285318 RRMM
Комментарии отсутствуют
Информация о видео
Другие видео канала
The role of FLT3 and IDH inhibitors in newly diagnosed older adults with AML based on ASH guidelines
The role of transfusion support in older patients with AML no longer receiving active therapy
Insights into the potential for a cure in myeloma: MRD negativity & CAR-T therapies
How may the subcutaneous OBI version of isatuximab impact the QoL of patients with MM?
Updated results of the Phase III PERSEUS trial evaluating dara-VRd in newly diagnosed myeloma
Frontline and R/R myeloma: an overview of the current treatment landscape
Genomics and immunotherapy: reshaping high-risk multiple myeloma treatment
Where do bispecifics and CAR-T stand in the current treatment landscape of Waldenström’s?
Genomic sequencing guides personalized treatment in multiple myeloma
Barriers community oncologists may face when implementing ASH guidelines in older patients with AML
ClonoSEQ in myeloma: how does it fit into a patient-centric diagnostic pathway?
Bispecific antibodies in myeloma: community care considerations & unmet needs
Key highlights from COMy 2026: quadruplet regimens, CAR-T, bispecifics, trispecifics, and more
Key unmet needs in functional high-risk myeloma: a clinical perspective
How is the role of sFLC evolving for assessing disease response in myeloma?
Insights into the updated genomic consensus definition for high-risk newly diagnosed myeloma
Recent advances and unmet needs in smoldering multiple myeloma
How may whole body MRI enhance patient management strategies in myeloma?
Expanding access to bispecific antibodies and CAR T-cell therapy in myeloma
Insights into the disease biology & role of T-cell redirecting therapies in EMD
